Holen Sie sich die Stockscreener-App
10.73
6.13%
0.62
Schlusskurs vom Vortag:
$10.11
Offen:
$10.2
24-Stunden-Volumen:
20,773
Relative Volume:
0.23
Marktkapitalisierung:
$68.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.48M
KGV:
-10.32
EPS:
-1.04
Netto-Cashflow:
$-28.71M
1W Leistung:
+13.54%
1M Leistung:
-26.81%
6M Leistung:
-32.90%
1J Leistung:
-27.87%
1-Tages-Spanne:
$10.20
$10.40
1-Wochen-Bereich:
$9.23
$10.70
52-Wochen-Spanne:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Firmenname
Forte Biosciences Inc
Sektor
Branche
Telefon
(310) 618-6994
Adresse
3060 PEGASUS PARK DRIVE, DALLAS, CA
Vergleichen Sie FBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
10.36 | 120.12M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.30 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.73 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.09 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.18 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.08 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Eingeleitet | TD Cowen | Buy |
| 2024-04-08 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Hochstufung | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Herabstufung | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Herabstufung | Truist | Buy → Hold |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-26 | Eingeleitet | Citigroup | Buy |
| 2020-08-28 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Eingeleitet | Truist | Buy |
Alle ansehen
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
What analysts say about Forte Biosciences Inc. stockRapid growth trajectories - jammulinksnews.com
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
Is Forte Biosciences Inc. a good long term investmentSuperior return velocity - Autocar Professional
What drives Forte Biosciences Inc. stock priceStrongest growth potential - PrintWeekIndia
Forte Biosciences Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
WVVI Stock Analysis and ForecastFree Bull & Bear Market Updates - Jammu Links News
Why Forte Biosciences Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Forte Biosciences Inc. stock price move sharplySafe Entry High Exit Alerts - Newser
How Forte Biosciences Inc. stock performs during market volatilityTop Momentum Stock Pick - Newser
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Forte Biosciences (FBRX): A Strategic Buy in Biotech's High-Reward Arena - AInvest
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week - Yahoo Finance
(FBRX) Investment Analysis and Advice - news.stocktradersdaily.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Index - MarketScreener
FBRX SEC FilingsForte Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Stock Sell-Offs Trigger Market Turmoil For Firms - Finimize
Firm Advises Forte Biosciences on $75 Million Public Offering - Wilson Sonsini
Forte Biosciences (FBRX) Plans $75 Million Public Offering - GuruFocus
Forte Biosciences Announces Public Offering of Shares - TipRanks
Forte Biosciences announces data from trial in celiac disease for FB102 - Yahoo Finance
Forte’s celiac disease drug shows positive results in Phase 1b trial - Investing.com Nigeria
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - New Castle News
Forte Biosciences (FBRX) Soars 16.75% on Positive Clinical Trial Results - AInvest
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Finanzdaten der Forte Biosciences Inc-Aktie (FBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Forte Biosciences Inc-Aktie (FBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):